2021
DOI: 10.3390/ph14111119
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4

Abstract: Antimitotic drugs that target tubulin are among the most widely used chemotherapeutic agents; however, the development of multidrug resistance has limited their clinical activity. We report the synthesis and biological properties of a series of novel 3-chloro-β-lactams and 3,3-dichloro-β-lactams (2-azetidinones) that are structurally related to the tubulin polymerisation inhibitor and vascular targeting agent, Combretastatin A-4. These compounds were evaluated as potential tubulin polymerisation inhibitors and… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 10 publications
(6 citation statements)
references
References 105 publications
0
5
0
Order By: Relevance
“…These MSAs have not reached the clinic, however, activity-dependent neuroprotective protein (ADNP), derived from NAP, remains a potential hope and is scheduled for future clinical trials ( Varidaki et al., 2018 ; Al-Horani and Kar, 2020 ; Santiago-Mujika et al., 2021 ). A recent addition to MSAs, sabizabulin, is currently in clinical trials as an antiviral drug, suggesting possible benefit in tauopathies (NCT04388826) ( Malebari et al., 2021 ).…”
Section: Treatment Strategies For Pathological Cell-cell Fusionmentioning
confidence: 99%
“…These MSAs have not reached the clinic, however, activity-dependent neuroprotective protein (ADNP), derived from NAP, remains a potential hope and is scheduled for future clinical trials ( Varidaki et al., 2018 ; Al-Horani and Kar, 2020 ; Santiago-Mujika et al., 2021 ). A recent addition to MSAs, sabizabulin, is currently in clinical trials as an antiviral drug, suggesting possible benefit in tauopathies (NCT04388826) ( Malebari et al., 2021 ).…”
Section: Treatment Strategies For Pathological Cell-cell Fusionmentioning
confidence: 99%
“…Combretastatins consist of two phenyl rings linked by a two-carbon bridge. The compound causes mitotic arrest in cancer cells, inhibits microtubule assembly and stimulates tubulin-dependent guanosine-5′-triphosphate hydrolysis [ 5 , 6 , 7 , 8 , 9 ]. Derivatives of combretastatin—CA4P (fosbretabulin), AVE8062 and ZD6186—are at stages 2/3 of clinical trials as anticancer drugs, acting on the mechanism of destabilizing microtubules and destroying the blood vessels of tumors [ 10 ].…”
Section: Introductionmentioning
confidence: 99%
“…Although the compounds were biologically evaluated as racemates, it was interesting that the 3 S ,4 R enantiomer of each compound was found to be ranked at lower energy in the docking study than the corresponding 3 R ,4 S enantiomer. We had previously reported stereochemical selectivity in docking energy calculated for related β-lactam compounds [ 54 , 105 ]. However, a very small difference was observed in the cellular efficacy of this series of compounds in the modelling study (e.g., IC 50 values in the range 10–61 nM), so it would not be expected to see a large difference in ranking.…”
Section: Resultsmentioning
confidence: 99%